Search - tctmd.com

Displaying 61 - 80 of 86

Sort: Relevancy | Date

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Presentation ACC 2020

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Presenter: Deepal L. Bhatt

March 30, 2020

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presentation ACC 2020

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presenter: Yangsoo Jang

March 30, 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

News Conference News ACC 2020

Safety, Efficacy of Ticagrelor Monotherapy Confirmed in Complex PCI, Diabetes

Yael L. Maxwell

March 30, 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

News Conference News ACC 2020

A-fib Patients Undergoing TAVR Do Better With OAC Alone: POPular TAVI

March 29, 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

March 28, 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

March 28, 2020

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

News Daily News

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

March 27, 2020

Conversations in Cardiology: Uncovered Struts on OCT After 12 Years?

News Opinion Conversations in Cardiology

Conversations in Cardiology: Uncovered Struts on OCT After 12 Years?

March 27, 2020

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

News Daily News

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

March 16, 2020

New ARISTOTLE Data ‘Reassuring’ on Lower Apixaban Dose

News Daily News

New ARISTOTLE Data ‘Reassuring’ on Lower Apixaban Dose

March 12, 2020

Late Cerebrovascular Events ‘Devastating’ in TAVR-Treated Patients

News Daily News

Late Cerebrovascular Events ‘Devastating’ in TAVR-Treated Patients

Michael O'Riordan

March 11, 2020

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

News Daily News

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

March 04, 2020

Antiplatelets Add Risk in Newly Diagnosed A-fib Patients: GARFIELD-AF

News Daily News

Antiplatelets Add Risk in Newly Diagnosed A-fib Patients: GARFIELD-AF

March 02, 2020

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

February 28, 2020

News Daily News

Bioprosthetic Valve Thrombosis Rare but Not Benign: New Insights

Yael L. Maxwell

February 28, 2020

Less Leaflet Thrombosis in Low-Risk TAVR Patients Treated With Oral Anticoagulation

News Conference News CRT 2020

Less Leaflet Thrombosis in Low-Risk TAVR Patients Treated With Oral Anticoagulation

Michael O'Riordan

February 26, 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

News Conference News CRT 2020

Small Study Hints Rivaroxaban Helps Cut Stroke in A-fib Patients Post-TAVR

February 24, 2020

ACC Releases Initial Cardiac Guidance on Novel Coronavirus

News Daily News

ACC Releases Initial Cardiac Guidance on Novel Coronavirus

February 13, 2020

Ticagrelor Hits Mark in Large Stroke Study: THALES Top-line Results

News Daily News

Ticagrelor Hits Mark in Large Stroke Study: THALES Top-line Results

Michael O'Riordan

January 27, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.